UMMS

Celebree School Raises $215,000 for Children's Hospitals Across the Country

Retrieved on: 
Monday, March 18, 2024
Culture, McDonald House, Leukemia, Partnership, Education, Research, Disability studies, Child, Infant, University, Charitable organization, UMMS, Aftercare, Kennedy Krieger Institute, Entrepreneurship, Curriculum, Social skills, Helsinki University Central Hospital, Parent, School, Toy

BALTIMORE, March 18, 2024 /PRNewswire/ -- Celebree School, a leader in early childhood education that provides infant and toddler care, preschool, before and aftercare, and summer camp programs, announced a record-breaking philanthropic year, with over $215,000 raised and donated to medical centers across the country that support children of all ages. The donation amount represents the collective fundraising efforts of Celebree, Caliday, and the Huffman Family foundation.  

Key Points: 
  • With philanthropic efforts at the forefront of Celebree School's focus, thousands of children will receive medical care and support from the contributions.
  • Celebree franchisee, Kate Mulcahy matched the Celebree School Enterprise donation of $10,000 to the Children's National Hospital, leading to a donation of $20,000.
  • In Boston, Celebree School donated $12,500 to the Boston's Children Hospital for a charity event where the team was able to tour the hospital with Celebree School franchisees, Nick and Nikki Foundas.
  • In 2024 Celebree School aims to beat its record of $215,000 by reaching for the total donations to exceed $225,000.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023
The New England Journal of Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Medical Affairs Bureau, Society, University of Maryland, College Park, Atopic dermatitis, Skin condition, Science, Maryland School, JAMA Dermatology, Hospital, Journal, Faculty, Prurigo nodularis, University, Physician, Service, Research, Paul Khavari, Johns Hopkins School of Medicine, Human musculoskeletal system, Knowledge, NIH, Skin, Duke University, Arthritis, Immunotherapy, FPI, University of Maryland School of Medicine, Diving Medical Advisory Council, MPH, University of Maryland Medical Center, Vinay Mohan Kwatra, UMMC, Wake Forest School of Medicine, Nature Medicine, UMMS, Joseph, Assistant professor, Pharmaceutical industry, Management, Medical device, Nursing, MD, Dermatology

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

LEADING HEALTHCARE EXECUTIVE RACHEL HOOVER, MS, MBA, NAMED EXECUTIVE VICE PRESIDENT AT UM FACULTY PHYSICIANS, INC.

Retrieved on: 
Friday, May 19, 2023
Proton, Faculty, Patient, Medical Affairs Bureau, UM, University, Education, AUC, UMMS, Physician, University of Maryland, College Park, MBA, Strategic planning, Radiation therapy, State Street Bank and Trust Company, Maryland School, University of Maryland School of Medicine, FPI, Johns Hopkins School of Medicine, University of Maryland Medical Center, Hospital, Isidore, Health, Hoover, Growth, Management, Nursing, MD

Hoover is a healthcare leader with more than 20 years of experience in providing strategic oversight and planning for enterprise-wide initiatives in academic and private health care systems.

Key Points: 
  • Hoover is a healthcare leader with more than 20 years of experience in providing strategic oversight and planning for enterprise-wide initiatives in academic and private health care systems.
  • Most recently she served as Chief Operating Officer for Johns Hopkins Regional Physicians and was previously Director of Global Services for Johns Hopkins Medicine.
  • "I am honored to step into this important role and to work with such an esteemed group of experts," said Ms. Hoover.
  • UMSOM faculty physicians conduct cutting-edge research and clinical trials and offer care in more than 40 medical specialties.

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, February 14, 2023
Oxford Biomedica, SIOX, Nine Months, Workforce, UMMS, Research, University of Massachusetts, RSL, Roivant Sciences, Cryptocurrency, Pharmaceutical industry

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.

Key Points: 
  • –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period
    –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval
    NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.
  • Research and development expenses were $1.9 million for the three months ended December 31, 2022 and $21.3 million for the three months ended December 31, 2021.
  • General and administrative expenses were $2.6 million for the three months ended December 31, 2022 and $4.1 million for the three months ended December 31, 2021.
  • The net loss for the fiscal third quarter ended December 31, 2022 was $4.0 million, or $0.05 per share, compared to a net loss of $25.5 million, or $0.35 per share, in the fiscal third quarter ended December 31, 2021.

Curation Health Announces Pilot Program with University of Maryland Medical System and CareFirst BlueCross BlueShield

Retrieved on: 
Tuesday, January 24, 2023
Blue Cross Blue Shield Association, University, UMMS, Health, University of Maryland St. Joseph Medical Center, University of Maryland Medical System, Hospital, Partnership, CareFirst BlueCross BlueShield, Physician, Workflow, Organization, Patient, Risk, Nursing, Collaboration

ANNAPOLIS, Md., Jan. 24, 2023 /PRNewswire/ -- Curation Health — creators of a value-based care platform facilitating provider-plan collaboration, has announced a strategic partnership with University of Maryland Medical System and CareFirst BlueCross BlueShield (CareFirst). This collaboration supports UMMS, CareFirst and Curation Health's shared commitment to improving population health and wellness and reducing the total cost of care through success in value-based care programs and innovation.

Key Points: 
  • Collaboration supports shift to Value-Based Care and focus on innovative solutions to advance accessible, affordable, quality care
    ANNAPOLIS, Md., Jan. 24, 2023 /PRNewswire/ -- Curation Health — creators of a value-based care platform facilitating provider-plan collaboration, has announced a strategic partnership with University of Maryland Medical System and CareFirst BlueCross BlueShield (CareFirst).
  • The Curation Health platform supports the provider workflow by integrating clinically relevant data from multiple sources into point-of-care workflow tools for closure of clinical and quality gaps over time.
  • The Curation Health platform will support the network through a piloted project with primary care providers at the University of Maryland St. Joseph Medical Group, a network of physicians affiliated with the University of Maryland St. Joseph Medical Center.
  • For more information on Curation Health and their prospective risk adjustment platform for value-based care, visit: curationhealth.co

Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, University of Massachusetts, Workforce, U.S. Securities and Exchange Commission, Research, Wind, Six Months in a Convent, RSL, Private Securities Litigation Reform Act, Oxford BioMedica, COVID-19, Annual report, UMMS, NASDAQ, SIOX, Roivant Sciences, NEW, Security (finance), Pharmaceutical industry

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal second quarter ended September 30, 2022.

Key Points: 
  • - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period
    - Strong cash position with $49.86 million of cash and cash equivalents as of September 30, 2022, expected to provide cash runway beyond December 2023
    NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal second quarter ended September 30, 2022.
  • We continue to conduct research activities relating to one pre-clinical program and also expect to provide an update on our strategic process by December 31, 2022, said David Nassif, J.D., Chief Executive Officer of Sio Gene Therapies.
  • Research and development expenses were $0.3 million for the three months ended September30, 2022 and $11.4 million for the three months ended September30, 2021.
  • The net loss for the fiscal second quarter ended September 30, 2022 was $3.1 million, or $0.04 per share, compared to a net loss of $21.2 million, or $0.29 per share, in the fiscal second quarter ended September 30, 2021.

LHC Group and University of Maryland Medical System announce home health partnership

Retrieved on: 
Tuesday, September 13, 2022
ACO, Securities Exchange Act of 1934, Risk, UMMS, University of Maryland Medical System, MD, System, Employee Retirement Income Security Act of 1974, Patient, Maryland School, Privacy, 8-K, Population, Health, University of Maryland Medical Center, Private Securities Litigation Reform Act, Partnership, Securities Act of 1933, Forward-looking statement, U.S. Securities and Exchange Commission, LHC, District, CEO, MBA, Terminology, Perception, Annual report, NASDAQ, Security (finance), Ageing, Hospital, University, Health insurance, Medicine

"Joining forces in Maryland with such an accomplished and respected health institution like UMMS is a great opportunity," said Keith Myers, LHC Group chairman and CEO.

Key Points: 
  • "Joining forces in Maryland with such an accomplished and respected health institution like UMMS is a great opportunity," said Keith Myers, LHC Group chairman and CEO.
  • UMMS is a private, university-based regional health system focused on serving the healthcare needs of Maryland.
  • UMMS' flagship academic campus, the University of Maryland Medical Center in Baltimore, is recognized regionally and nationally for excellence in specialized care.
  • The University of Maryland Medical System (UMMS) is an academic private health system, focused on delivering compassionate, high-quality care and putting discovery and innovation into practice at the bedside.

Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Wind, U.S. Securities and Exchange Commission, GM1, Private Securities Litigation Reform Act, GLOBE, National Human Genome Research Institute, NEW, GM2, Security (finance), Research, Workforce, Annual report, UMMS, SIOX, NASDAQ, COVID-19, University of Massachusetts School of Law, University, National, Cryptocurrency, Pharmaceutical industry

NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022.

Key Points: 
  • Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023
    NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022.
  • We are also continuing to actively pursue strategic alternatives that could deploy our cash for better returns to our stockholders, said David Nassif, J.D., Chief Executive Officer of Sio Gene Therapies.
  • For the fiscal first quarter ended June 30, 2022, research and development expenses were $5.5 million, a decrease of $2.5 million compared to the fiscal first quarter ended June 30, 2021.
  • The net loss for the fiscal first quarter ended June 30, 2022 was $8.4 million, or $0.11 per share, compared to a net loss of $11.9 million, or $0.16 per share, in the fiscal first quarter ended June 30, 2021.

Mt. Washington Pediatric Hospital's President & CEO Announces Plans to Retire

Retrieved on: 
Tuesday, May 24, 2022
Adolescence, Children's Hospital Association, Mt. Washington Pediatric Hospital, American College, Johns Hopkins Hospital, Board of directors, Leadership, Patient, University of Maryland Medical System, Nursing, JHM, Shelly, Association, University of Florida Obsessive Compulsive Disorder Program, Rehabilitation, ACHE, American Animal Hospital Association, Culture, Retirement, MWPH, Trustee, Partnership, Phyllis, UMMS, Board, University, Sheila, Infant, Jack, Johns Hopkins School of Medicine, Trauma, HOPE, Johns Hopkins Bayview Medical Center, Growth, Daily Record, CEO, Management, Medicine, Hospital, Pharmaceutical industry

BALTIMORE, May 24, 2022 /PRNewswire-PRWeb/ -- Mt. Washington Pediatric Hospital (MWPH), a leader in pediatric care for 100 years, announced that Sheldon "Shelly" Stein, President and CEO, is retiring with plans to remain in his role through November 2022 to support this transition.

Key Points: 
  • Washington Pediatric Hospital (MWPH), a leader in pediatric care for 100 years, announced that Sheldon "Shelly" Stein, President and CEO, is retiring with plans to remain in his role through November 2022 to support this transition.
  • For two decades, Stein's leadership has been instrumental in elevating MWPH as a leader in post-acute pediatric care.
  • Washington through numerous challenges and milestones during his 20 years as CEO," said Fred Wolf III, the chair of MWPH's Board of Trustees.
  • Washington Pediatric Hospital celebrates 100 years of providing family-focused, coordinated care to all children, including those with serious, chronic, or complex medical needs.

ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine Models for Novel Gene Therapy in Maple Syrup Urine Disease at the 25th ASGCT Meeting

Retrieved on: 
Saturday, May 21, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education, BCKDHA, School, University of Massachusetts Medical School, Leucine, Allotransplantation, MSUD, University, Diet, Haemophilia, Animal, ASC, Phenotype, Gene, Clinic, Biomedical sciences, Therapy, Clinical trial, DBT, UMass Memorial Health, Research, Mouse, Cerebral edema, UMMS, RNA, Duke University School of Medicine, Genetic disorder, University of Massachusetts, Maple, Commonwealth, Doctor of Philosophy, Health, BCAA, Clinic for Special Children, Partnership, Human, Maple syrup urine disease, Graduate school, Cell, MD, CSC, Valine, Organic acid, Lists of diseases, Patient, Society, BCKDHB, Industry, AAV, Calf, Life, Isoleucine, Safety, Intussusception (medical disorder), Mayo Clinic Graduate School of Biomedical Sciences, Mutation, Precision medicine, CEO, Vaccine, Milk, Medical device, Pharmaceutical industry, Research, Genetics, Clinical Trials, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education

The partnership designed a dual-function AAV9 gene replacement vector that was administered via intravenous (IV) injection.

Key Points: 
  • The partnership designed a dual-function AAV9 gene replacement vector that was administered via intravenous (IV) injection.
  • Surviving mice grew and behaved similar to normal littermates and had normal or nearly normal biochemical markers with unrestricted diet for 16 weeks.
  • As compared to MSUD patients, MSUD calves exhibit a similar phenotype and are closely matched for size and metabolic rate.
  • In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education.